Casgevy and Lyfgenia were both approved by the FDA to treat sickle cell disease. Both treatments also cost millions of dollars.

Although its causes are still poorly understood, new data from the CDC shows chronic fatigue syndrome is more common than previously thought.

A new study of tirzepatide, the main ingredient in Mounjaro and Zepbound, finds that weight loss gains are hard to maintain after treatment ends.

A clinical trial suggests younger post-menopausal women with early-stage HR-positive/HER2-negative breast cancer may safely omit radiation therapy if they continue endocrine therapy.

Swift, who was named ‘2023 Person of the Year’ by Time, also stopped drinking alcohol to prepare.